tiprankstipranks
Blurbs

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bluebird Bio (BLUE) and Merck & Company (MRK)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bluebird Bio (BLUEResearch Report) and Merck & Company (MRKResearch Report).

Bluebird Bio (BLUE)

In a report released today, Mani Foroohar from Leerink Partners maintained a Hold rating on Bluebird Bio, with a price target of $8.00. The company’s shares closed last Tuesday at $5.03, close to its 52-week low of $4.04.

According to TipRanks.com, Foroohar is ranked 0 out of 5 stars with an average return of -18.5% and a 35.9% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, 4D Molecular Therapeutics, and Recursion Pharmaceuticals.

The word on The Street in general, suggests a Hold analyst consensus rating for Bluebird Bio with a $7.00 average price target, representing a 35.1% upside. In a report released today, Cowen & Co. also downgraded the stock to Hold.

See Insiders’ Hot Stocks on TipRanks >>

Merck & Company (MRK)

In a report released today, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company, with a price target of $100.00. The company’s shares closed last Tuesday at $83.72.

According to TipRanks.com, Graybosch ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -12.2% and a 36.4% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Silverback Therapeutics, Werewolf Therapeutics, and Bolt Biotherapeutics.

Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $92.80, which is a 10.9% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $100.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BLUE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More